Patents Assigned to KM Biologics Co., Ltd.
-
Publication number: 20240159751Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.Type: ApplicationFiled: November 20, 2023Publication date: May 16, 2024Applicants: Kyoto University, KM Biologics Co., Ltd.Inventors: Koichiro HATA, Shinji Uemoto, Hirofumi Hirao, Toyonari Kubota
-
Patent number: 11957325Abstract: A nebulizer capable of reliably intermittently applying a biological tissue adhesive is provided. A biological tissue adhesive nebulizer includes a first tube 30 for injecting a first solution containing a first component, and a second tube 30 for injecting a second solution containing a second component that promotes clot formation of the first component. The first solution injected from the first tube and the second solution injected from the second tube are mixed to generate and spray a biological tissue adhesive. A partition wall 34 is provided between a distal end 31 of the first tube and a distal end 31 of the second tube.Type: GrantFiled: March 21, 2022Date of Patent: April 16, 2024Assignee: KM BIOLOGICS CO., LTD.Inventors: Yoshitaka Takegawa, Naoya Kawakami, Kazunori Yamanaka
-
Patent number: 11952398Abstract: A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood coagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.Type: GrantFiled: June 9, 2021Date of Patent: April 9, 2024Assignee: KM Biologics Co., Ltd.Inventors: Kentaro Ebisu, Takashi Kai, Nozomi Matsuo
-
Publication number: 20230248821Abstract: An object of the present invention is to provide an effective vaccine that can prevent and treat infection with CMV. A fusion protein of the present invention is a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of the cytomegalovirus (CMV). A vaccine for prevent or treat infection with cytomegalovirus (CMV) of the present invention is a subunit vaccine containing a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of CMV as an antigen.Type: ApplicationFiled: June 8, 2021Publication date: August 10, 2023Applicant: KM Biologics Co., Ltd.Inventors: Masaharu Torikai, Hiroaki Mori, Kohsuke Hazeyama, Miyuki Matsumoto
-
Publication number: 20230168251Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.Type: ApplicationFiled: December 6, 2022Publication date: June 1, 2023Applicants: KYOTO UNIVERSITY, KM BIOLOGICS CO., LTD.Inventors: Koichiro HATA, Shinji UEMOTO, Hirofumi HIRAO, Toyonari KUBOTA
-
Patent number: 11567080Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.Type: GrantFiled: January 6, 2017Date of Patent: January 31, 2023Assignees: KYOTO UNIVERSITY, KM BIOLOGICS CO., LTD.Inventors: Koichiro Hata, Shinji Uemoto, Hirofumi Hirao, Toyonari Kubota
-
Patent number: 11472867Abstract: An anti-HSV monoclonal antibody or an antigen-binding fragment thereof is an anti-HSV gB monoclonal antibody or an antigen-binding fragment thereof that specifically binds to herpes simplex virus (HSV) envelope glycoprotein B (gB), comprising: a heavy chain variable region comprising a heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, a heavy chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 4, and a heavy chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 5; and a light chain variable region comprising a light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 6, a light chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 7, and a light chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 8.Type: GrantFiled: August 29, 2018Date of Patent: October 18, 2022Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroaki Mori, Tomohiro Nishimura, Hiroyuki Shimizu, Akihiro Koube
-
Publication number: 20220296227Abstract: A nebulizer capable of reliably intermittently applying a biological tissue adhesive is provided. A biological tissue adhesive nebulizer includes a first tube 30 for injecting a first solution containing a first component, and a second tube 30 for injecting a second solution containing a second component that promotes clot formation of the first component. The first solution injected from the first tube and the second solution injected from the second tube are mixed to generate and spray a biological tissue adhesive. A partition wall 34 is provided between a distal end 31 of the first tube and a distal end 31 of the second tube.Type: ApplicationFiled: March 21, 2022Publication date: September 22, 2022Applicant: KM Biologics Co., Ltd.Inventors: Yoshitaka TAKEGAWA, Naoya KAWAKAMI, Kazunori YAMANAKA
-
Patent number: 11433160Abstract: A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.Type: GrantFiled: October 22, 2019Date of Patent: September 6, 2022Assignees: TEIJIN LIMITED, KM BIOLOGICS CO., LTD.Inventors: Yukako Kageyama, Kentaro Fujinaga, Ayuko Yamaguchi, Yusuke Akiyama, Akitoshi Oono, Susumu Honda, Makoto Satake, Hiroaki Kaneko, Takayuki Imamura, Ryoichi Kawamura, Masaki Hirashima
-
Publication number: 20220275347Abstract: Provided is an oncolytic virus having both improved safety and productivity. Provided are: a conditionally replicating vaccinia virus which lacks the functions of a vaccinia virus growth factor (VGF), an extracellular signal-regulated kinase (ERK) activation protein, and a ribonucleotide reductase (RNR), is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety; and a conditionally replicating vaccinia virus which lacks the functions of a VGF, an ERK activation protein, and an RNR, is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety and productivity, and in which a gene encoding an extracellular enveloped virus (EEV)-related protein is substituted with a gene corresponding to another vaccinia virus strain having a high EEV-producing ability.Type: ApplicationFiled: August 7, 2020Publication date: September 1, 2022Applicant: KM Biologics Co., Ltd.Inventors: Toshio MURAKAMI, Go OKITA, Yui KAMIZURU
-
Publication number: 20220265896Abstract: A problem to be solved by the present invention is to provide a fibrosis inhibitor that solves the problem of inhibiting fibrosis of an organ or tissue surface, and especially of inhibiting fibrosis of an epicardial surface. Furthermore, by inhibiting fibrosis, the present invention prevents or reduces subsequent development of adhesions to avoid organ or tissue damage during re-operation. Provided is a fibrosis inhibitor for inhibiting fibrosis of a tissue by fixing a biocompatible polymer to a tissue where it is desirable to inhibit fibrosis.Type: ApplicationFiled: July 31, 2020Publication date: August 25, 2022Applicant: KM Biologics Co., Ltd.Inventors: Hideki SAGA, Minako INUI, Noriko OGURA
-
Patent number: 11421002Abstract: A modified protein of a herpes simplex virus (HSV) envelope glycoprotein B (gB), in which at least one non-neutralizing antibody-inducing epitope (non-neutralizing epitope) present in domain IV and domain I of wild-type HSV gB is inactivated (de-epitoped).Type: GrantFiled: August 29, 2018Date of Patent: August 23, 2022Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroaki Mori, Tomohiro Nishimura, Hiroyuki Shimizu, Miyuki Matsumoto
-
Patent number: 11357847Abstract: The modified HSV gD protein of the present invention is a modified protein of a herpes simplex virus (HSV) envelope glycoprotein D (gD), wherein the modified HSV gD protein is derived from a wild-type HSV gD by modification of at least one of B cell epitopes having low or no neutralizing antibody-inducing activity compared to a B cell epitope present in a receptor-binding domain (RBD) (decotopes) in the ectodomain of the wild-type HSV gD, so that the modified epitope does not function as an epitope.Type: GrantFiled: August 29, 2018Date of Patent: June 14, 2022Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroaki Mori, Tomohiro Nishimura, Hiroyuki Shimizu, Akihiro Koube, Takahiro Katayama
-
Publication number: 20220111035Abstract: A novel vaccine antigen for prevention of Respiratory Syncytial Virus (RSV) infection is created which surpasses conventional vaccines comprising as an antigen RSV F protein alone in view of efficacy and/or safety. A vaccine is prepared which comprises as an antigen a RSV F/G chimeric protein wherein a portion of RSV F protein as a basic structure is replaced with a whole or a portion of Conserved Central Domain sequence of RSV G protein or wherein a whole or a portion of Conserved Central Domain sequence of RSV G is added to the basic structure. As a result of assessment of both efficacy and safety, a vaccine comprising as an antigen the F/G chimeric protein of the present invention confirmed to be more excellent than a vaccine comprising as an antigen RSV F protein alone in view of efficacy and/or safety.Type: ApplicationFiled: February 27, 2020Publication date: April 14, 2022Applicant: KM Biologics Co., Ltd.Inventors: Ryo YAMAUE, Satoshi KAMAKURA, Mihoko MATSUO, Masaharu TORIKAI, Hiroaki MORI
-
Patent number: 11186630Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.Type: GrantFiled: February 6, 2020Date of Patent: November 30, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Masaharu Torikai, Akihiko Hosoi, Tomoyo Takeo, Masayo Ueno, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su, Mineyuki Mizuguchi
-
Publication number: 20210292359Abstract: A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood couagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.Type: ApplicationFiled: June 9, 2021Publication date: September 23, 2021Applicant: KM Biologics Co., Ltd.Inventors: Kentaro EBISU, Takashi KAI, Nozomi MATSUO
-
Patent number: 11059857Abstract: A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood coagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.Type: GrantFiled: December 20, 2017Date of Patent: July 13, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Kentaro Ebisu, Takashi Kai, Nozomi Matsuo
-
Patent number: 11027005Abstract: A method for preparing a PRP conjugate having high storage stability and a method for producing a Hib conjugate vaccine are provided. A method for preparing PRP conjugate in accordance with the embodiments of the present invention is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP for a coupling reaction between PRP and a carrier protein. Also, a Hib conjugate vaccine comprising as an antigen the PRP conjugate prepared by said method has excellent storage stability and maintain sufficient immunogenicity.Type: GrantFiled: October 11, 2017Date of Patent: June 8, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Makoto Moriyama, Katsuhiko Fukada, Kazuhiko Kimachi, Yuki Mihara, Hiroshi Yonemura, Yoichiro Kino
-
Patent number: 10881723Abstract: The present invention relates to a vaccine containing fixed virus particles, wherein a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles.Type: GrantFiled: January 10, 2017Date of Patent: January 5, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroto Onuma, Yukari Tsurudome, Kazuyuki Ikeda, Ryo Yamaue, Kazuhiko Kimachi, Motoharu Abe, Akihiro Watanabe, Yuki Ohara
-
Patent number: 10774321Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.Type: GrantFiled: May 20, 2015Date of Patent: September 15, 2020Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroshi Nakatake, Masaki Hirashima, Hideki Takeo, Reiko Matsuyama, Wataru Morikawa